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1. Considerações Iniciais 
CONSIDERAÇÕES INICIAIS 
A hipertensão arterial essencial é uma condição de resistência à 
insulina, independente da obesidade ou de outras alterações metabólicas (1,2). 
Ferranini, ao estudar pacientes hipertensos, sem obesidade ou intolerância à glicose, 
também demonstrou que os tecidos periféricos, e não o fígado, são o sítio de 
resistência à ação da insulina nestes pacientes. Portanto, a ação da insulina em inibir 
a neoglicogênese hepática está preservada, mantendo a glicemia de jejum dentro 
dos valores normais. Porém há menor captação periférica de glicose em relação aos 
indivíduos magros e normotensos, o que resulta níveis de glicemia mais elevados 
aos 120 minutos após sobrecarga oral com 75 gramas de glicose (G2h) (1). Entre os 
tecidos periféricos, o músculo esquelético parece ser o local com maior resistência à 
ação da insulina nos pacientes hipertensos. Desta forma, observa-se redução não só 
da captação de glicose, mas também da vasodilatação induzida pela insulina, com 
conseqüente redução do fluxo sanguíneo para o tecido muscular esquelético (3). 
Considerando que os pacientes hipertensos apresentam diminuição da 
captação periférica de glicose estimulada pela insulina, com conseqüente alteração 
da G2h (1-4), a utilização da glicemia de jejum isolada como critério para diagnóstico 
de alterações da tolerância à glicose nestes pacientes tem sido questionada (5-8). 
Salmasi e col. demonstraram que  40% dos pacientes hipertensos com glicemia de 
jejum menor que 110 mg/dl  apresentavam alteração da G2h e recomendaram a 
realização do teste oral de tolerância à glicose (TOTG) em todos os pacientes 
hipertensos (7). Portanto, apesar da glicemia de jejum isolada ser o critério 
atualmente recomendado pela Associação Americana de Diabetes (ADA) para 
diagnóstico das anormalidades do metabolismo da glicose na prática clínica (9), ela é 
incapaz de diagnosticar alterações da G2h em uma importante parcela da população 
hipertensa (5,7). Este fato tem sérias implicações clínicas e vem sendo amplamente 
discutido, visto que a G2h está associada a alterações deletérias  do endotélio (10,11) e 
é um forte preditor de mortalidade cardiovascular (12-19). No estudo DECODE 
(Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe), 
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25364 indivíduos foram acompanhados prospectivamente durante aproximadamente 
sete anos, e o maior número de mortes ocorreu nos indivíduos com tolerância 
diminuída à glicose, principalmente naqueles com glicemia de jejum normal (15). 
Corroborando estes dados, Agewall também demonstrou que a G2h alterada foi um 
fator de risco independente para mortalidade cardiovascular em uma população de 
homens hipertensos acompanhados durante seis anos (19). De fato, a recomendação 
da utilização da glicemia de jejum isolada foi feita com base na incidência e 
prevalência de uma complicação microvascular, a retinopatia diabética, e não após 
avaliação da mortalidade por complicações macrovasculares (20). 
Entretanto, o alto custo do TOTG para ser utilizado com fins 
diagnósticos em toda população hipertensa tem estimulado a busca por parâmetros 
simples e reprodutíveis que identifiquem os pacientes que devem ser submetidos a 
este teste. Alguns estudos propõem a utilização de modelos predtivos da alteração 
da G2h, combinando alguns dados clínicos e laboratoriais como glicemia de jejum, 
hemoglobina glicada e idade dos pacientes (5,21). Porém, até a publicação do nosso 
estudo, esta avaliação ainda não havia sido realizada na população hipertensa 
considerando o ponto de corte de 100 mg/dL para glicemia de jejum, conforme 
estabelecido pela ADA em sua última recomendação (9).   
A preocupação em diagnosticar adequadamente as alterações do 
metabolismo da glicose em pacientes hipertensos se justifica devido à alta 
prevalência de diabetes e intolerância à glicose nesta população, (5,22-24) 
particularmente naqueles em tratamento anti-hipertensivo (25).  
Além de estar associada à maior risco de diabetes e intolerância à 
glicose, a hipertensão arterial apresenta uma forte associação com a obesidade (26-28). 
O ganho de peso influencia linearmente o aumento da pressão arterial (29), enquanto 
discretas reduções de peso também estão associadas à diminuição dos valores 
pressóricos (30). O padrão de distribuição de gordura também tem sido valorizado, 
tanto que Sironi e cols descreveram a adiposidade visceral como uma característica 
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inerente ao fenótipo do paciente hipertenso e quantitativamente relacionada tanto ao 
grau de hipertensão arterial quanto ao grau de resistência à insulina (27).  
Muitos mecanismos têm sido propostos para explicar o 
desenvolvimento da hipertensão arterial na obesidade (31,32). A ativação do sistema 
nervoso simpático por substâncias produzidas no tecido adiposo, tais como 
leptina (33), angiotensinogênio (34) e ácidos graxos (35) é um dos mecanismos já 
estabelecidos.  Na obesidade, o aumento de ácidos graxos livres, angiotensina II, 
TNF-α e endotelina-1 induz à ativação de serina-quinases, como por exemplo a 
proteína quinase C, que altera a fosforilação do receptor de insulina , diminuindo a  
sinalização intracelular da insulina e prejudicando a formação de óxido nítrico e a 
vasodilatação endotélio dependente. Adicionalmente, leva à hiperativação da via 
que induz à proliferação das células da musculatura lisa vascular, contribuindo para 
o processo aterosclerótico (36-38). A hiperinsulinemia compensatória contribui para a 
manutenção desta condição de resistência à insulina, visto que prejudica a sua 
própria sinalização no fígado e no músculo e também induz à proliferação celular na 
parede vascular (39), além de contribuir também para a ativação do sistema nervoso 
simpático (40). Outros mecanismos envolvidos na hipertensão associada à obesidade 
são o aumento do número de receptores de depuração do peptídeo natriurético atrial 
e diminuição da sua atividade no rim (41), além de alterações renais estruturais e 
funcionais, com o desenvolvimento de uma glomerulopatia relacionada à 
obesidade (42). 
 Em especial, a ativação do sistema renina-angiotensina (SRA) tem 
sido descrita como um dos mecanismos mais importantes responsáveis pela 
hipertensão arterial associada à obesidade (35,43). É interessante destacar que esta 
ativação ocorre mesmo na presença da retenção de sódio e expansão do volume 
extracelular desencadeados pela ativação do sistema nervoso simpático (44,45). Engeli 
e cols demonstraram que os indivíduos obesos apresentam aumento de vários 
componentes circulantes do SRA, tais como angiotensinogênio, renina, enzima 
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conversora da angiotensina e aldosterona. Nestes mesmos pacientes, foi evidenciada 
uma redução significante dos componentes do SRA na circulação após perda de 5% 
do peso corpóreo (43). Corroborando estes dados, o antagonismo da aldosterona 
também foi efetivo em reduzir a pressão arterial em cães que desenvolveram 
hipertensão associada à obesidade (46). Recentemente, foi demonstrada a expressão 
de vários componentes do SRA no tecido adiposo em animais e humanos (35,47-49). 
Em animais, foi descrito o aumento da transcrição do gene do angiotensinogênio 
especificamente na gordura intra-abdominal (50). Porém, a contribuição do SRA 
localizado no tecido adiposo para o aumento de seus componentes na circulação 
ainda vem sendo estudada. O angiotensinogênio proveniente do tecido adiposo 
contribui para o aumento do angiotensinogênio circulante em animais (35,49) e está 
envolvido no aumento da pressão arterial (49). Já em cultura de pré adipócitos 
humanos foi demonstrada produção local de angiotensina II (51).  
Quando a obesidade e a hipertensão arterial estão associadas, somam-
se duas condições que passam a ter um efeito aditivo, levando à maior resistência à 
insulina e hiperinsulinemia compensatória (25). Portanto, ao escolher o tratamento 
anti-hipertensivo dos pacientes obesos ou com acúmulo de gordura abdominal, os 
efeitos metabólicos destes medicamentos devem ser levados em conta. Os efeitos 
deletérios dos diuréticos tiazídicos sobre o metabolismo da glicose, com aumento 
do risco de desenvolvimento de diabetes, já foram amplamente demonstrados (52-55). 
A depleção de potássio, induzida por estes medicamentos, ainda que pequena, é 
descrita por vários autores como o principal fator que leva à alteração da 
homeostase da glicose nestes pacientes (56-58). Tanto a diminuição da secreção de 
insulina (57,59) quanto a diminuição da sensibilidade à insulina (60) foram descritos, 
apesar de algumas controvérsias em relação a esta última (59). Entre os mecanismos 
pelos quais os diuréticos tiazídicos levam à depleção de potássio, estão a ativação 
do SRA em resposta à contração volumétrica, troca de potássio por sódio no túbulo 
distal e entrada de potássio nas células devido à alcalose induzida pelo diurético (61). 
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Em suma, os pacientes portadores de hipertensão arterial e obesidade 
apresentam maior resistência à ação da insulina e importante ativação do SRA. 
Estes pacientes freqüentemente são tratados com diuréticos tiazídicos, os quais 
também levam à ativação do SRA e aumentam o risco de desenvolvimento de 
diabetes. Portanto, a hipótese na qual os pacientes obesos em uso destas medicações 
seriam mais propensos à depleção de potássio e intolerância à glicose é muito 
provável e ainda não havia sido estudada. Diante do crescente aumento da 
prevalência da obesidade, é de grande importância que a interação entre obesidade 
abdominal e uso de diuréticos tiazídicos seja avaliada, visto que ambas as condições 
estão associadas à alterações do metabolismo da glicose (53-55,62,63) e freqüentemente 
coexistem no mesmo paciente. 
Os dois trabalhos a serem apresentados abordam o impacto da 
hipertensão arterial na resistência à insulina. No primeiro artigo, o fato da 
hipertensão arterial ser um estado de resistência periférica à insulina, com alteração 
predominante da glicemia pós prandial, será considerado ao se discutir o melhor 
método diagnóstico para identificar as mulheres hipertensas com alteração do 
metabolismo da glicose. Já no segundo artigo, avaliaremos a freqüente interação 
entre duas condições de risco para o desenvolvimento de intolerância à glicose e 
diabetes nos pacientes hipertensos: a presença de obesidade abdominal e o uso de 
diuréticos tiazídicos. Discutiremos as principais alterações metabólicas decorrentes 
desta associação e a importância da escolha de um anti-hipertensivo com perfil 
metabólico favorável ao tratar pacientes hipertensos com este fenótipo.   
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ABSTRACT 
 
Essential hypertension is a condition of peripheral insulin resistance; 
thus fasting plasma glucose (FPG) alone may not identify glucose tolerance 
abnormalities. To evaluate the value of an FPG of 100 mg/dl in the detection of 
these abnormalities in hypertensive women and to identify clinical markers of high 
risk of glucose intolerance indicative of further investigation, the authors studied 
313 hypertensive women, without known diabetes, in whom an oral glucose 
tolerance test (OGTT) was performed. The authors demonstrated that FPG alone 
was unable to identify 27.6% of hypertensive women with glucose intolerance. In 
this subgroup the association of waist circumference (WC) ≥ 97 cm and FPG ≥ 90 
mg/dl increased the risk of glucose intolerance with an odds ratio of 6.97. The 
authors suggest that OGTT should be performed in hypertensive women with 
normal FPG but with FPG ≥ 90 mg/dl and waist circumference  ≥ 97 cm.  
 
Keywords: Hypertension, Glucose tolerance, Diabetes, Oral glucose tolerance. 
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INTRODUCTION 
 
In 1997, the American Diabetes Association (ADA) changed the 
diagnostic criteria for diabetes previously established by the National Diabetes Data 
Group and the World Health Organization (WHO). The changes involved lowering 
the fasting plasma glucose level (FPG) threshold for diabetes from the value of 140 to 
126 mg/dl, introducing the new category “impaired fasting glucose” (IFG) and 
recommending the use of FPG as the reference diagnostic method for diabetes instead 
of 2-hour plasma glucose after an oral glucose tolerance test (2h-PG) (1). In 2003, the 
ADA reduced the cutoff to define IFG from ≥ 110 mg/dL to ≥ 100 mg/dL (2), and 
recently referred to patients with IFG and/or impaired glucose tolerance (IGT) as 
having “pre-diabetes”, indicating the existence of risk factors for future diabetes and 
cardiovascular disease (3). In these publications, however, the ADA did not change the 
recommendation that FPG must remain the test of choice in clinical practice (1-3), in 
spite of the WHO diagnostic criteria that retained the use of 75-g oral glucose 
tolerance test (OGTT) and the 2h-PG for diagnostic purposes (4).  
The ADA’s decision to use FPG alone for the diagnosis of glucose 
abnormalities has been criticized based on several studies that have demonstrated that 
IGT, characterized as postprandial hyperglycemia, is associated with more adverse 
cardiovascular risk factor (5,6) and is more adequate to predict cardiovascular 
mortality (7-12), especially in older patients (13,14), because postchallenge glucose levels 
increase to a much greater extent with advancing age than does FPG (15). In addition, 
IGT is a risk factor for atherosclerosis, and postprandial hyperglycemia may exert 
detrimental effects on endothelium, as previously demonstrated by the association 
between postchallenge hyperglycemia with carotid intima-media thickness and 
diffuse coronary artery narrowing (16,17). One of the most relevant studies addressing 
this question was Diabetes Epidemiology: Collaborative Analysis Of Diagnostic 
Criteria in Europe (DECODE) (10), in which 2h-PG was associated with an increased 
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risk of death, regardless of FPG levels, and that the larger number of excess deaths 
occurred in individuals with IGT, mainly in those with normal FPG. 
Furthermore, adding to the fact that the patients with IGT do not have 
the same prognostic value than patients with IFG as described above, these two 
abnormalities have different pathophysiologic features with distinct metabolic 
determinants. FPG is influenced by insulin sensitivity in the liver to control hepatic 
glucose output; in patients with IFG, reduced hepatic insulin sensitivity combined 
with impairments in basal and first-phase insulin releases causes fasting 
hyperglycemia. The 2h-PG depends on peripheral insulin sensitivity to control the 
glucose uptake in the muscle; in patients with IGT, this abnormality combined with 
impairments in first and second-phase insulin responses, causes postprandial 
hyperglycemia (18-21). 
Essential hypertension is a condition of peripheral insulin 
resistance (22,23) in patients receiving either no treatment or antihypertensive 
treatment (24) with resultant post prandial glucose abnormalities; thus we have 
argued for the use of FPG in the diagnosis of glucose abnormalities in treated 
hypertensive patients. Therefore, in this study we evaluated the ability of an FPG 
criterion of 100 mg/dl to detect these abnormalities in hypertensive women and 
identified clinical markers of high risk of glucose intolerance indicative of further 
investigation. 
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PATIENTS AND METHODS 
To assess the agreement between the diagnosis established by 
measuring FPG and that obtained by using the 2h-PG, a comparative cross-sectional 
study was planned. The protocol of this analysis was approved by the Institutional 
Ethics Committee. 
We analyzed 313 hypertensive women who met the following criteria: 
treatment in our outpatient clinic for obesity, dyslipidemia or hypertension; no 
previous diagnosis of diabetes or other glucose abnormalities, as defined by the 
2003 ADA (2) and the 1998 WHO criteria (4); and submission to an OGTT at our 
institution between 2001 and 2004. Data on participants’ height, weight, waist 
circumference, FPG and 2h-PG during OGTT were obtained. Participants were 
considered to have previously diagnosed diabetes if they reported having diabetes or 
having used anti-diabetic medication. They were compared with 45 normotensive 
patients without glucose tolerance abnormalities, who were treated in our outpatient 
clinic for obesity or dyslipidemia. 
Glucose tolerance was classified using either the 2003 ADA (2) and the 
1998 WHO classification (4). The ADA classification recommends only the fasting 
plasma glucose sample for clinical use to classify the fasting glucose level as 
normal (< 100 mg/dL), impaired (100-125 mg/dL), or diabetes (≥ 126 mg/dL) (2). 
The WHO classification recommends using both the fasting and the 2-hour glucose 
sample. The fasting values are the same as in the ADA recommendations (2); 2h-PG 
values, in accordance with the WHO recommendations, are as follows: normal,      
< 140 mg/dL; impaired, 140-199 mg/dL; and indicative of diabetes, ≥ 200mg/dL (4). 
We included patients classified as hypertensive according to the 1999 
WHO definition: systolic blood pressure ≥ 140 mmHg, diastolic blood pressure 
≥ 90 mmHg (25) or current use of antihypertensive medication.  
In every case, the OGTT was performed after a 12-h overnight fast 
and a 75g oral glucose overload. Blood samples were drawn at baseline and 120 
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minutes after the glucose challenge for measurement of plasma glucose. Plasma 
glucose was measured using the glucose oxidase method. Plasma insulin was 
determined by monoclonal antibody – based immunofluorimetric assay, but insulin 
was not measured in all patients. On the morning of the OGTT, patients underwent 
a physical examination, with blood pressure and anthropometric measurements 
(height, weight, and waist and hip circumferences). Blood pressure was measured 
by mercury sphygmomanometry after the patient rested for 5 minutes in the sitting 
position. Body mass index (BMI) was calculated as weight in kilograms divided by 
height in meters squared.  
Insulin resistance was assessed only in the patients who had both 
fasting plasma insulin and 2h after OGTT insulin measurements, and they were 221 
patients. The homeostatic model assessment insulin resistance index (HOMA R) 
was used (26,27). 
 
Statistical Analysis 
Statistical analyses were performed using SPSS version 12.0 software 
for Windows (SPSS, Inc, Chicago, IL) One-way analysis of variance was used to 
compare of means of clinical and metabolic features among the groups and post hoc 
Tukey test was performed. Data were presented as mean ± SD. To determine the 
variables of high- risk 2h-PG abnormalities, at first, patients with normal fasting 
plasma glucose (< 100 mg/dl) were analyzed through univariate analysis and 2-PG 
≥ 140 mg/dl was used as the dependent variable. Based on the results of univariate 
analysis, receiver operating characteristic (ROC) curve established the cutoff values 
with better sensitivity and specificity for the variables identified, and positive and 
negative predictive values were calculated. In a further calculation, logistic 
regression analysis determined the influence of the parameter sets on 2h-PG 
abnormalities, and the odds ratio for this glucose intolerance in hypertensive women 
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with normal FPG and with the established clinical variables were calculated with a 
95% confidence interval (CI). Statistical significance was determined as P < 0.05. 
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RESULTS 
 
Diagnosis of Glucose Tolerance Abnormalities 
After the analysis of the 358 women in whom OGTT was performed, 
we stratified the participants into 4 groups: normotensive patients with normal 
glucose tolerance were classified as the NNT group (n=45), while the hypertensive 
patients with normal glucose tolerance (FPG < 100 mg/dL and 2h-PG < 140 mg/dL) 
were classified as the HNT group (n=134). The HFG group consisted of 
hypertensive patients with FPG ≥ 100 mg/dL, regardless of the glucose post load 
abnormalities, (n=128), who were diagnosed by FPG alone. The HG2h group 
comprised hypertensive patients with FPG < 100 and 2h-PG ≥ 140 mg/dL (n=51), 
who would not be identified by FPG alone – even using the lower cutoff for 
impaired fasting glucose recommended by the ADA. 
Therefore, among the 313 hypertensive women in whom OGTT was 
performed, 179 (57.2%) had abnormal glucose tolerance. The isolate determination 
of FPG according to the new ADA criteria, which suggests the utilization of the 
lower cutoff of 100 mg/dl, failed to detect impaired glucose tolerance in 51 (27.6%) 
of the 185 hypertensive women with normal FPG.   
 
Patients’ Clinical and Metabolic Characteristics 
The clinical characteristics of the study subjects are shown in Table I. 
When compared to normotensive patients without glucose abnormalities (NNT 
group), persons in the 3 groups of hypertensive patients (HNT, HFG, and HG2h) 
were older and more obese and had greater waist circumference and greater waist-
to-hip ratio. The hypertensive group with abnormal glucose tolerance (HFG and 
HG2h) had a greater waist circumference than did those with hypertension with 
normal glucose tolerance, and only those in the HFG group were older and more 
obese than the hypertensive women with normal glucose tolerance. The 
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characteristics of the hypertensive patients with normal fasting glucose, but with 2h-
PG abnormalities (HG2h group) did not differ from the those of patients identified 
by FPG alone (HFG group), except in that the HFG participants were older 
(p=0.024).  
The metabolic characteristics of study participants are presented in 
Table II. Hypertensive patients (including patients with normal glucose metabolism) 
presented higher fasting insulin values than the patients without hypertension did, 
and the HFG group had the highest fasting insulin level. Only the hypertensive 
patients with abnormal glucose tolerance (HFG and HG2h groups) presented a 
higher insulin level after glucose load, however. Concerning insulin resistance, the 
HFG group had the highest HOMA-R of all the groups. As demonstrated, the 
characteristics of the patients with 2h-PG abnormalities (HG2h group) did not differ 
from the patients identified by the FPG alone (HFG group), except that the HFG 
participants had greater fasting insulin level and a higher HOMA-R . 
 
Prediction of 2h-PG Abnormalities 
Independent associations of the continuous variables fasting plasma 
insulin, fasting plasma glucose, age, waist circumference, BMI, systolic and 
diastolic blood pressure, HOMA R and high-density lipoprotein cholesterol with the 
dependent variable 2h-PG were first analyzed by univariate analysis. Only three of 
these variables were found to be significant in predicting the 2-hour glucose 
abnormalities: FPG (mg/dL) (odds ratio [OR]: 1.066; 95%CI 1.018-1.116; 
P=0.007), waist circumference (cm) (OR: 1.024; 95%CI: 1.005-1.042; P=0.011) 
and BMI (kg/m²) (OR: 1.056; 95% CI: 1.011-1.102; P=0.013). We could not use 
waist circumference and BMI in the same model due to multicolinearity; thus, we 
decided to use waist circumference since the area under the ROC curve was 
significant for this variable (area: 0.606; P=0.025), but only marginally significant 
for the BMI (area: 0.592; P=0.054). 
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The ROC curve established the values for these variables with the best 
sensitivity and specificity to indicate 2h-PG abnormalities. The cutoff value 
established for waist circumference was 97 cm in women with a sensitivity of 
70.6%, a specificity of 50.7%, a positive predictive value of 35.3% and negative 
predictive value of 81.9%; the cutoff value for FPG was 90 mg/dL with a sensitivity 
of 62.7%, a specificity of 58.2%, a positive predictive value of 36.4% and a 
negative predictive value of  80.4%. 
Based on the results of univariate analysis and after determining the 
cutoff values using the ROC curve, we performed a multivariate logistic regression 
analysis. Hypertensive women with FPG ≥ 90 mg/dL presented an OR of 2.294 
(95%CI: 1.145-4.593; P=0.019) when compared with women with lower FPG, 
while the hypertensive women with waist circumference ≥ 97 cm presented an OR 
of  2.219 (95%CI: 1.097-4.488; P=0.027) when compared to women with smaller 
waist circumference. When both conditions (waist circumference ≥ 97 cm and 
fasting plasma glucose ≥ 90 mg/dL) were present the OR increased to 6.97 (95%CI: 
2.216-21.93; P = 0.001). 
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DISCUSSION 
 
Our results have demonstrated that a significant number of 
hypertensive women without a previous diagnosis of diabetes (57.2%) presented 
with glucose tolerance abnormalities. There are some studies that reported the 
prevalence of diabetes in the hypertensive population and the results varied among 
the different studies, from a 13% prevalence in the Losartan Intervention for 
Endpoint reduction in hypertension (LIFE study) (28) to 21.7% described by Bur and 
associates (29) to up to a 31.7% prevalence in the Valsartan Antihypertensive long-
term Use Evaluation (VALUE) trial (30). Few studies have determined the 
prevalence of glucose tolerance abnormalities, not only diabetes, in hypertensive 
persons who were not known to have diabetes; only a recent publication has 
demonstrated these abnormalities in 58% of 152 hypertensive patients (29). This 
prevalence has not yet been determined according to the 2003 ADA classification, 
and our study was the first to use the lower cut point of 100 mg/dL to determine this 
prevalence in the hypertensive population.  
We demonstrated that 27.6% of the women with normal FPG showed 
2h-PG ≥ 140 mg/dL on OGTT and would not have been identified as having 
glucose intolerance if only FPG was determined. No studies in the hypertensive 
population that have used the cutoff of 100 mg/dL for FPG have been published, 
but other studies have demonstrated that FPG criterion has failed to detect diabetes 
in 31% of  persons in a European general population study (31), diabetes or IGT in 
41.3% of those in a population at high risk for diabetes (32) and abnormal 2h-PG in 
48% of those in a hypertensive population (33).  
Therefore, our results further support the importance of OGTT for the 
diagnosis of glucose tolerance abnormalities in patients with arterial hypertension. 
The high cost of the OGTT being used for diagnostic purposes in all of the 
hypertensive population supports the strategy of using other reasonable parameters to 
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determine in which patients this test must be performed. Our study demonstrated that 
FPG ≥ 90 mg/dl and waist circumference ≥ 97 cm were parameters indicative of 2h-
PG abnormalities with ORs of 2.294 and 2.219 respectively; when these 2 conditions 
were present, the OR for glucose intolerance reached 6.97. There are other studies 
that have proposed some predictive models of 2h-PG abnormalities (34-37), but few 
publications proposed different models in the hypertensive population combining 
FPG, glycated hemoglobin (29) and age (38). Our results corroborate those of a 1999 
study (31) concerning the use of FPG to recommend OGTT. Our results differ from 
those of the Pre-Diabetes Score (PreDiSc) study (38), which suggested that only the 
patients with abnormal capillary fasting glucose in the range of 100-130 mg/dL 
should be screened for the model proposed and the venous fasting glucose ≥ 110 
mg/dL should be one of the screening parameters. In contrast, we identified higher 
FPG within the normoglycemic range as an independent predictor of 2h-PG 
abnormalities. No other study evaluated variables that were able to identify glucose 
intolerance in hypertensive patients with normal FPG. The value of ≥ 90 mg/dl 
identified by the ROC curve in our study was exactly the same as described 
previously, not as a predictor of glucose intolerance, but as a predictor of diabetes in a 
general population of young men (39). 
Concerning the clinical and metabolic characteristics of the study 
participants, the finding that characteristics of the hypertensive patients with normal 
FPG, but with 2h-PG abnormalities (HG2h group) did not differ from the patients 
identified by the FPG alone (HFG group) (except for that the HFG participants were 
older, which was already describe at DECODE) (10), was of particular interest. This 
result confirms our assertion that both groups have the same clinical characteristics 
and needs to be treated; however the HG2h group may not be recognized when we 
use fasting glucose alone. 
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It is important to remember that our study included only Brazilian 
women and other waist circumference values should be considered when analyzing 
women from different ethnic groups. 
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CONCLUSIONS 
 
Our data suggest that OGTT must be performed in hypertensive 
women with FPG 90-100 mg/dL and with a waist circumference ≥ 97 cm, because 
the OR of 6.97 for glucose intolerance when both characteristics are present seems 
to be clinically relevant. Women with these conditions deserve special care in the 
choice of antihypertensive drugs, because some of these agents can worsen insulin 
resistance (40,41). These women also deserve greater attention regarding the blood 
pressure target, which should be appropriate for high risk individuals. In addition, 
life style changes (42-44) should be encouraged and pharmacologic interventions to 
improve insulin sensitivity or reduce postprandial hyperglycemia (44-46) should be 
considered, with the goal of preventing progression to type 2 diabetes and 
cardiovascular diseases (47).   
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TABLES 
Table 1: Comparison of Clinical Characteristics Among Groups. 
 NNT HNT HFG HG2h P 
Age (y) 42.7 ± 11.0 
(n=45) 
49.5 ± 9.8a
(n=133) 
54.5 ± 8.4ab
(n=128) 
50.9 ± 10.6ac
(n=51) 
< .001 
BMI (kg/m2) 30.5 ± 6.1 
(n=45) 
33.0 ± 6.8a
(n=134) 
35.5 ± 6.5ab
(n=128) 
35.1 ± 7.1a
(n=51) 
< .001 
Waist circumference 
(cm) 
89.8 ± 15.1 
(n=45) 
98.9 ± 16.4a
(n=134) 
104.6 ± 14.1ab
(n=128) 
104.2 ± 16.7ab
(n=51) 
< .001 
Waist-to-hip ratio 0.87 ± 0.10 
(n=45) 
0.90 ± 0.08a
(n=120) 
0.92 ± 0.08a
(n=115) 
0.91 ± 0.09a
(n=45) 
.003 
Heart rate 78.7 ± 3.9 
(n=44) 
75.2 ± 8.8 
(n=109) 
76.8 ± 8.0 
(n=88) 
77.0 ± 7.9 
(n=38) 
.054 
Systolic blood 
pressure (mmHg) 
121.7 ± 9.7 
(n=45) 
147.4 ± 17.7a
(n=120) 
147.8 ± 20.4a
(n=114) 
142.0 ± 16.3a
(n=45) 
< .001 
Diastolic blood 
pressure (mmHg) 
81.5 ± 7.6 
(n=45) 
92.7 ± 9.6a
(n=120) 
91.7 ± 11.7a
(n=114) 
90.1 ± 11.0a
(n=45) 
< .001 
a P<.05 vs NNT group; b P<.05 vs HNT group; c P<.05 vs HFG group 
NNT: normotensive patients with normal glucose tolerance 
HNT: hypertensive patients with normal glucose tolerance (fasting plasma glucose level [FPG] < 
100 mg/dL and 2-hour plasma glucose level [2h-PG] < 140 mg/dL) 
HFG: hypertensive patients with FPG ≥ 100 mg/dL, regardless of glucose post-load abnormalities, 
who were diagnosed by FPG alone 
HG2h: hypertensive patients with FPG < 100 mg/dL and 2h-PG  ≥ 140 mg/dL 
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Table 2: Comparison of the Metabolic Characteristics Among Groups. 
 NNT HNT HFG HG2h P 
FPG (mg/dL) 85.1 ± 7.8 
(n=45) 
88.1 ± 7.6 
(n=134) 
112.1 ± 11.8ab
(n=128) 
91.0 ± 6.6ac
(n=51) 
< .001 
2h-PG (mg/dL) 105.3 ± 21.4 
(n=45) 
105.8 ± 21.8 
(n=134) 
163.6 ± 51.1ab
(n=128) 
162.7 ± 23.3ab
(n=51) 
< .001 
Fasting insulin 
(pmol/l) 
10.8 ± 7.4 
(n=42) 
14.1 ± 8.8a
(n=87) 
21.6 ± 9.7ab
(n=59) 
15.4 ± 10.0ac
(n=33) 
< .001 
2-Hour insulin 
(pmol/L) 
63.8 ± 44.9 
(n=42) 
71.2 ± 49.9 
(n=87) 
106.7 ± 65.0ab
(n=59) 
132.0 ± 99.9ab
(n=33) 
< .001 
HOMA-R 2.3 ± 1.6 
(n=42) 
3.1 ± 2.0 
(n=87) 
6.1 ± 3.1ab
(n=59) 
3.5 ± 2.4c
(n=33) 
< .001 
Total cholesterol 
(mg/dL) 
203.8 ± 48.6 
(n=45) 
204.0 ± 37.1 
(n=134) 
214.4 ± 39.0 
(n=128) 
207.2 ± 34.9 
(n=51) 
.180 
HDL cholesterol 
(mg/dL) 
55.0 ± 21.3 
(n=45) 
45.1 ± 12.7a
(n=134) 
46.2 ± 13.3a
(n=128) 
48.6 ± 13.5 
(n=50) 
.004 
LDL cholesterol 
(mg/dL) 
122.9 ± 41.7 
(n=45) 
133.1 ± 32.7 
(n=126) 
137.9 ± 33.8 
(n=123) 
128.8 ± 30.7 
(n=45) 
.070 
Triglycerides  
(mg/dL) 
129.2 ± 69.6 
(n=45) 
136.7 ± 71.8 
(n=134) 
149.7 ± 100.2 
(n=128) 
136.2 ± 62.8 
(n=51) 
.469 
a P<.05 vs NNT group; b P<.05 vs HNT group; c P<.05 vs HFG group 
NNT: normotensive patients with normal glucose tolerance 
HNT: hypertensive patients with normal glucose tolerance [fasting plasma glucose level (FPG) < 
100 mg/dL and 2-hour plasma glucose level (2h-PG) < 140 mg/dL] 
HFG: hypertensive patients with FPG ≥ 100 mg/dL, regardless of glucose post-load abnormalities, 
who were diagnosed by FPG alone 
HG2h: hypertensive patients with FPG < 100 mg/dL and 2h-PG  ≥ 140 mg/dL 
HOMA-R: homeostatic model assessment insulin resistance index 
HDL: high-density lipoprotein 
LDL: low-density lipoprotein 
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ABSTRACT 
 
The inadvertent activation of renin angiotensin system (RAS) is an 
important mechanism that contributes to hypertension in obese individuals. 
Thiazide diuretics also activate RAS in response to volume contraction and can lead 
to a decrease in serum potassium values and glucose metabolism abnormalities. To 
evaluate the impact of abdominal obesity on potassium depletion and glucose 
homeostasis in hypertensive patients on thiazide therapy, we have studied 329 
hypertensive patients, without known diabetes or impaired renal function. Patients 
were stratified into two major groups according to the use or not of thiazide diuretic 
therapy and each group was further divided in two subgroups according to the 
presence of abdominal obesity. We demonstrated that obese patients on diuretic 
therapy showed lower plasma potassium levels and higher glucose values compared 
to non-obese patients on diuretic therapy. In conclusion, abdominal obesity 
predisposes to potassium depletion during diuretic therapy with consequent 
repercussion on glucose homeostasis.  
 
Keywords: Hypertension, Waist circumference, Thiazide diuretic, Potassium depletion, 
Plasma glucose. 
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INTRODUCTION 
 
Abdominal obesity and arterial hypertension are the main components 
of metabolic syndrome accounting for an increase in its prevalence (1). Arterial 
hypertension was described as the most frequent diagnostic criterion of metabolic 
syndrome in both genders of an apparently health Japanese population (2). The 
association between obesity, especially abdominal obesity, and hypertension has 
been demonstrated by several studies (3,4). Abdominal obesity is clinically measured 
by the waist circumference (5), which was defined as “hypertriglyceridemic waist” 
due to its ability, in association with fasting triglycerides levels, to identify 
individuals at increased risk of coronary heart disease (6). In addition, this pattern of 
fatty distribution has been described as an independent risk factor for arterial 
hypertension (7) and type 2 diabetes (8), and has been associated with the metabolic 
syndrome also in individuals with normal body weight (9).  
Several mechanisms have been proposed to explain the development 
of hypertension in obesity (10). In particular, the inadvertent activation of the 
systemic and adipose renin angiotensin system (RAS) has been described as an 
important mechanism (11,12), even in the presence of sodium retention and volume 
expansion resulting from the enhanced sympathetic activity (13,14). Increased levels 
of circulating components of RAS were observed in obese individuals, showing a 
significant decrease after weight loss (12). In addition, a functional RAS located in 
the adipose tissue has been demonstrated (11,15,16). Enhanced circulating levels of 
angiotensinogen originated from the adipose tissue was demonstrated in animals 
studies (13,17), while local production of angiotensin II was described in cultured 
human preadipocytes (18).  
Essential hypertension is an insulin-resistant state per se, even in the 
absence of obesity or other metabolic abnormalities (19). This may explain the higher 
prevalence of glucose intolerance in hypertensive patients (20), particularly in those 
on antihypertensive therapy (21). In addition, the association of obesity and 
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hypertension seems to have an addictive effect, leading to a higher insulin resistance 
state and hyperinsulinemia (21).  
It is well established that thiazide diuretics can lead to a decrease in 
serum potassium levels (22) and glucose metabolism abnormalities with increased 
risk of diabetes (23,24). Potassium depletion is attributed to the activation of RAS in 
response to volume contraction, enhanced potassium exchange with sodium in 
distal tubule and entering of potassium into the cells due to diuretic-induced 
alkalosis (22). Potassium depletion (25,26), even with mild reductions (27,28), has been 
associated with glucose intolerance. The proposed mechanisms responsible for this 
association are reduced insulin release (26,28) and peripheral insulin resistance (29).  
Considering that obese hypertensive patients are highly insulin-
resistant and prone to glucose intolerance and RAS activation, the aim of our study 
was to evaluate whether the presence of abdominal obesity would contribute to a 
more severe potassium depletion and higher glucose values in hypertensive patients 
on thiazide therapy. A secondary objective was to quantify the impact of central 
obesity on cardiovascular risk in this population of hypertensive patients.  
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METHODS 
 
In a cross-sectional study 329 hypertensive patients followed in our 
institution were analyzed between May 2005 and May 2006. The protocol was 
approved by the Institutional Ethics Committee and all participants provided written 
informed consent.  
In the present study, patients treated for dyslipidemia, with a previous 
diagnosis of diabetes and with abnormal renal function were excluded. Diabetes 
was defined a fasting plasma glucose ≥ 126 mg/dL and/or 2-hour postload glucose ≥ 
200 mg/dL (30), self-reported history of diabetes or use of antidiabetic medication. 
Abnormal renal function was defined as serum creatinine higher than 1.2 mg/dL.  
Hypertension was defined as systolic blood pressure ≥ 140 mmHg and 
/ or diastolic blood pressure  ≥  90 mmHg (31) or current use of antihypertensive 
medication. 
After a 12-hours overnight fasting, the patients were submitted to a 
medical interview, physical examination with blood pressure and anthropometric 
measurements (height, weight and waist circumference) and laboratory assessment. 
During the medical consultation, information on demographic factors, personal 
medical history, current medications, smoking, and postmenopausal status in 
women were obtained. Waist circumference was taken as the middle point between 
the costal margin and the iliac crest. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. Blood pressure was 
measured in the sitting position, after 5 minutes of rest, using a mercury 
sphygmomanometer with the appropriate cuff size. 
Concerning the laboratory parameters assessment, plasma potassium 
was determined by ion selective electrodes and albumin by colorimetric method. 
Fasting plasma glucose, uric acid, total cholesterol and triglycerides (TG) were 
determined by enzymatic colorimetric methods. HDL cholesterol was measured by 
homogeneous colorimetric enzymatic method and LDL cholesterol was calculated 
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by the Friedwald formula: LDL cholesterol = Total cholesterol - (HDL cholesterol + 
TG / 5). The analyzer used was HITACHI 912, Roche. Plasma C-reactive protein 
(CRP) was determined by imunochemoluminescence assay and the kit used was 
Diagnostic Products Corporation Medlab, with analytical sensitivity of 0.01 mg/dL, 
intra assay variability of 4.2 to 6.4% and inter assay variability of 4.8 to 10%. 
Serum creatinine was measured through alkaline picrate assay. Renal function was 
determined by creatinine clearance through the Modification of Diet in Renal 
Disease (MDRD) Study Equation (32). The cardiovascular risk was assessed through 
the Framingham score proposed by the National Cholesterol Education Program in 
its third report on Detection, Evaluation and Treatment of High Blood Cholesterol 
in Adults (NCEP-ATP III) to determine the risk of a coronary event in 10 years (33). 
Plasma C-reactive protein (CRP) was determined in 319 patients. 
Among them, 52 patients with CRP > 1 mg/dL were not evaluated regarding this 
variable, due to the possibility of association with acute inflammatory processes (34).   
Patients were stratified into two major groups according to the use (T 
group) or not (NT group) of thiazide diuretic therapy. Each group was further 
divided in two subgroups according to the presence of abdominal obesity, defined 
by the waist circumference > 88 cm for women and > 102 cm for men as proposed 
by the NCEP-ATPIII criterion for metabolic syndrome diagnosis (33). Therefore, 
within each major group of patients there were subgroups of patients with (AO 
subgroup) and without abdominal obesity (NAO subgroup)   
 
Statistical Analyzes 
The two major groups (T and NT groups) were analyzed separately. 
Within each group, continuous variables with normal distribution were analysed by 
Student’s t-test to compare AO and NAO subgroups. Only the continuous variable 
PCR was not normally distributed and was analyzed through the nonparametric 
Mann-Whitney test. Chi-square test analyzed the association of categorical 
variables. Continuous variables normally distributed were expressed as mean ± 
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standard deviation, C reactive protein was expressed as median and interquartile 
range and categorical variables were expressed in percentages. 
Two separate multiple linear regressions were performed in all 
patients. In the first one, serum potassium was considered the dependent variable, 
while waist circumference, thiazide use and of angiotensin-converting-enzime 
inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) use were the 
independent variable. In the second analysis, plasma glucose was the dependent 
variable and waist circumference, thiazide use, ACEIs or ARBs use and plasma 
potassium were the independent variables.  
Statistical significance was determined as P value < 0.05. 
Statistical analyses were performed using SPSS version 12.0 software 
for Windows. 
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RESULTS 
 
Table I shows clinical characteristics of all patient subgroups. Except 
for the frequency of women, there were no differences concerning age, smoking, 
post-menopausal status, arterial hypertension and use of other anti-hypertensive 
classes when comparing the two subgroups of patients (AO and NAO) within each 
group (T and NT groups). Moreover, no differences in the doses of thiazide 
diuretics were observed between the patients in AO and NAO subgroups within the 
T group. The majority of patients were on 25 mg/day of thiazide therapy, both in 
NAO (74.3%) and AO (79%) subgroups. Only 3% of patients in both subgroups 
were on 50 mg and the remaining was on 12.5 mg/day of thiazide diuretic. In 
addition, patients from T group were receiving a greater percentage of anti-
hypertensive therapy, including ACEIs and ARBs (71.8% vs 48.2%; p<0.001), 
calcium-channel blockers (32.4% vs 17.0%; p=0.002) and β blockers (25.5% vs 
12%; p=0.002) than patients in the NT group.  
Table II shows the patient’s metabolic characteristics, cardiovascular 
risk and renal function. The presence of abdominal obesity was associated with 
higher levels of uric acid, CRP and Framingham cardiovascular risk score in both T 
and NT groups and most of the patients was classified in the low and intermediate 
risk category with the Framingham cardiovascular risk score. However, only in the 
T group, abdominal obesity was associated with higher plasma glucose and lower 
plasma potassium. Also in the T group, 8.3% developed hypokalemia, defined as 
plasma potassium level < 3.6 mEq/L: 4% in the NAO-T and 4.3% in the AO-T 
subgroups. Conversely, only in the NT group, plasma HDL cholesterol values were 
lower and Triglycerides-to-HDL cholesterol ratio (TG/HDL cholesterol ratio) was 
higher in AO than in NAO subgroup. 
Considering all patients together, two distinct multiple linear 
regressions were performed and the interactions among the variables were tested. In 
the first one, we evaluated the influence of waist circumference, thiazide use and 
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ACEI or ARB use on plasma potassium values. In the second analysis, we 
examined the influence of waist circumference, thiazide use, ACEI or ARB use and 
serum potassium on plasma glucose. The findings from the first regression model 
showed that waist circumference (P=0.041) and use of thiazides diuretics (P<0.001) 
were independently associated with the plasma potassium values, while the second 
regression analyses showed that waist circumference (P=0.046) and serum 
potassium (P=0.034) were independently associated with plasma glucose 
abnormalities.  
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DISCUSSION 
 
In our study, the association of abdominal obesity with higher levels 
of plasma C-reactive protein, uric acid and Framingham score in both T and NT 
groups are in accordance with previous findings that consider obesity a condition of 
sub-clinical chronic inflammation (35) and central fat distribution a risk factor for 
cardiovascular diseases (6).  There is a strong association between CRP and total and 
abdominal obesity (36), since the adypocites (37) and macrophages, mainly in omental 
adipose tissue, produce interleukin-6 which in turn induces CRP synthesis in the 
liver (38). Uric acid values have been also related to obesity (39) and impaired urate 
renal clearance, induced by hyperinsulinemia, seems to be the main responsible 
mechanism in individuals with insulin resistance (40). In our study, diuretic therapy 
did not interfer in these differences observed between patients with and without 
abdominal obesity. Although Framingham score was higher in patients with 
abdominal obesity, they were classified in the low and intermediate risk category. 
This may be, in part, due to the fact that diabetic patients, who are considered in the 
high risk category for coronary artery disease (CAD), were not included. Another 
explanation would be that Framingham Point Scoring System may underestimate 
the CAD risk of obese patients with metabolic syndrome. It assesses a low short-
term risk and does not consider many of the elements of metabolic syndrome, which 
could be important to evaluate CAD risk in a longer than 10 years period of 
time (41).  
Recent studies have described a functional RAS located in the adipose 
tissue, with expression of many of the RAS components (11,15-17). In animals, an 
increased transcription of angiotensinogen in the intra-abdominal fat was 
described (42) and the enhanced secretion of angiotensinogen into the circulation was 
associated with increased blood pressure (17). Finally, Engeli et al demonstrated that 
circulating components of RAS are increased in obesity (12). Therefore, the 
activation of adipose and systemic RAS seems to be one of most important 
 48
ARTIGO 2 
mechanisms of obesity related hypertension (11). In fact, Paula et al also 
demonstrated that aldosterone has an important role in the hypertension-related 
obesity and that aldosterone antagonism was effective in reducing blood pressure in 
dogs with obesity-induced hypertension (43). In our study, only obese patients on 
diuretic therapy showed lower plasma potassium levels, suggesting that abdominal 
obesity predisposes to potassium depletion during diuretic therapy suggesting that 
RAS activation could be involved.  
Concerning glucose metabolism, our obese hypertensive non diabetic 
patients showed higher plasma glucose levels in association with lower plasma 
potassium values (although within the normal range), during diuretic therapy. 
Considering all patients together, linear regressions also indicated that thiazide use 
and abdominal obesity independently predispose to reductions in plasma potassium, 
with further repercussion on glucose homeostasis. These findings are in accordance 
with previous reports describing even mild potassium depletion as a mechanism 
leading to glucose intolerance in patients on thiazides diuretics (27,28). Helderman 
demonstrated that oral potassium supplementation prevented glucose intolerance 
during diuretic therapy and also suggested that changes in glucose metabolism 
induced by diuretic therapy were attributed to potassium depletion (26). Both 
decrease in insulin secretion (26,28) and in peripheral insulin sensitivity (29) are 
described as mechanisms of glucose intolerance in these patients. Among the 
mechanisms of impaired insulin secretion are the reduced beta-cell responsiveness 
to glucose stimulus (26,28), high proportion of pro-insulin in circulation (44), abnormal 
initial insulin release phase (44) and opening of calcium-activated potassium 
channels (45). The reduction in insulin-mediated glucose disposal was previously 
described (29), but there are controversies (28). Rowe et al has described only 
impaired insulin secretion, and not abnormal peripheral tissue sensitivity, with diet 
induced potassium depletion (28). In addition, the mechanism underlying the 
decrease of insulin-mediated glucose disposal is still unclear.  
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 The increased risk of diabetes associated with the use of thiazides has 
been described in several studies (23,24). Verdecchia et al demonstrated that baseline 
fasting plasma glucose and diuretic treatment were the independent predictors of 
new onset diabetes in a population of hypertensive patients followed during 16 
years (46). 
It was previously described that the metabolic effect of small doses of 
diuretic may be blunted by the concomitant use of an ACEI (47). However, our 
results indicate that abdominal obesity may predispose to thiazide-induced changes 
in serum potassium and plasma glucose, even during the use of RAS blockers.  
Although plasma potassium and glucose differed among subgroups on 
diuretic therapy, the TG/HDL cholesterol ratio of these patients was similar. In the 
group of patients without diuretic, it was observed that the TG/HDL cholesterol 
ratio was higher in the obese, compared to non obese subgroup. These results 
suggest that obesity interfere on lipid profile, while the influence of thiazides may 
also occur in the subgroups of lean patients. According to previous studies, 
increased TG/HDL cholesterol ratio is a metabolic marker of insulin resistance (48). 
This increased ratio seems to be strongly associated with small LDL particles (49), 
which are more atherogenic than the large size LDL particles and  predictive of 
CAD (50).  
In conclusion, given the increasing prevalence of obesity worldwide, 
our study has provided a new insight concerning the interaction between abdominal 
obesity and diuretic therapy as an important mechanism contributing to changes in 
glucose homeostasis in hypertensive patients. Therefore, particularly in obese 
insulin-resistant patients, the choice of antihypertensive therapy must take into 
account not only its effects on blood pressure, but also its deleterious influence on 
glucose and lipid profiles. 
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TABLES 
Table 1: Comparison of hypertensive patient clinical characteristics according to 
the use of thiazide diuretics and NCEP criteria for the circumference waist 
measurement. 
 NT group T group 
 
NAO 
subgroup 
(n=67) 
AO 
subgroup 
(n=74) 
P 
value 
 
NAO 
subgroup 
(n=74) 
AO  
subgroup 
(n=114) 
P value 
 
Age (years) 56.7 ± 11.4 57.1 ± 10.8 .827 58.6 ± 10.4 57.2 ± 8.5 .319 
Women (%) 59.70 85.13 .001 62 93.8 < .001 
Postmenopausal  
(%) 
73.0 76.6 .689 80.9 79.0 .796 
ACEIs and/or 
ARBs use (%) 
41.8 54.1 .146 72.0 71.0 .775 
Β-blockers use (%) 16.4 8.1 .130 28.4 23.7 .471 
Calcium-channel 
blocker use (%) 
19.4 14.8 .474 36.4 29.8 .340 
Current smoker 
(%) 
13.4 8.1 .306 8.1 7.9 .958 
Metabolic 
Syndrome (%) 
7.4 54.0 < .001 9.4 52.6 < .001 
BMI (kg/m²) 24.6 ± 3.2 31.4± 4.1 < .001 25.7 ± 3.0 32.7 ± 4.8 < .001 
SBP (mmHg) 140.5 ± 19.0 137.8 ± 16.0 .356 140.2 ± 17.8 139.0 ± 19.4 .681 
DBP (mmHg) 86.6 ± 10.9 85.7 ± 8.4 .567 86.6 ± 11.1 87.8 ± 9.6 .676 
NT group: patients without thiazide therapy 
T group: patients on thiazide therapy 
NAO subgroup: patients without abdominal obesity 
AO subgroup: patients with abdominal obesity 
ACEIs: angiotensin-converting-enzime inhibitors 
ARBs: angiotensin-receptor blockers 
BMI: body mass index 
SBP: systolic blood pressure 
DBP: diastolic blood pressure 
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Table 2: Comparison of laboratory parameters according to the use of thiazide 
diuretics and the NCEP criteria for the circumference waist measurement. 
 Patients without thiazide 
diuretics use ( NT group) 
Patients in use of thiazide 
diuretics   (T group) 
 NAO 
subgroup 
(n=67) 
AO 
subgroup 
(n=74) 
P 
value  
 
NAO 
subgroup 
(n=74) 
AO 
subgroup 
(n=114) 
P 
value  
 
Framinghan 
Score 
12.9 ± 4.7 14.5 ± 4.3 .038 13.8 ± 3.7 15.2 ± 3.5 .010 
Creatinine 
clearance 
(MDRD) 
73.2 ± 12.7 72.4 ± 13.8 .719 72.5 ± 9.5 69.7 ± 11.5 .070 
C-reactive 
protein (mg/l) 
0.15 
(0.08-0.31) 
0.32 
(0.17-0.48) 
< .001 
0.13 
(0.08-0.24) 
0.38 
(0.18-0.58) 
< .001 
Fasting plasma 
glucose (mg/dl) 
83.7 ± 11.8 86.0 ± 9.8 .206 84.8 ± 8.4 87.7 ± 10.9 .039 
Uric Acid 
(mg/dl) 
5.1 ± 1.5 5.6 ± 1.4 .045 5.2 ± 1.4 5.7 ± 1.4 .015 
Serum Potassium 
(mEq/L) 
4.5 ± 0.41 4.5 ± 0.44 .784 4.4 ± 0.50 4.2 ± 0.45 .013 
Total Cholesterol 
(mg/dl) 
217.5±37.2 218.5±36.7 .877 208.6±36.1 214.7±39.0 .289 
HDL Cholesterol 
(mg/dl) 
62.9±17.7 56.0±12.9 .010 61.6±18.5 57.8±11.2 .115 
LDL Cholesterol 
(mg/dl) 
129.9±33.6 133.4±34.7 .436 117.5±29.4 126.7±34.9 .061 
Triglycerides 
(mg/dl) 
129.0±60.0 146.0±65.5 .117 140.4±75.0 143.8±57.1 .732 
TG/HDL ratio 2.28 ± 1.33 2.86 ± 1.77 .032 2.62 ± 1.82 2.64 ± 1.30 .948 
NT group: patients without thiazide therapy 
T group: patients on thiazide therapy 
NAO subgroup: patients without abdominal obesity 
AO subgroup: patients with abdominal obesity 
HDL: high-density lipoprotein 
LDL: low-density lipoprotein 
TG/HDL ratio: triglycerides/HDL cholesterol ratio 
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FIGURE 
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Figure 1: Comparison of plasma potassium, plasma gluocse and TG/HDL cholesterol 
ratio between patients with (AO+) and without abdominal obesity (AO-) divided 
according to diuretic therapy. 
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4. Principais Achados e Conclusões 
PRINCIPAIS ACHADOS E CONCLUSÕES 
PRINCIPAIS ACHADOS 
 Identificou-se alteração do metabolismo da glicose em 57,2% das 
mulheres hipertensas, 
 Em 27,6% das mulheres hipertensas com glicemia de jejum normal 
observou-se tolerância diminuída à glicose e diabetes. 
 Entre as mulheres hipertensas com glicemia de jejum normal, aquelas 
com glicemia de jejum entre 90 e 100 mg/dl e com circunferência da 
cintura ≥ 97 cm apresentaram uma razão de risco 6,97 vezes maior de 
tolerância diminuída à glicose e diabetes que as pacientes hipertensas 
sem estas características. 
 A obesidade abdominal predispõe à depleção de potássio durante o uso 
de diuréticos tiazídicos, com repercussões na glicemia, mesmo na 
vigência do uso de bloqueadores do sistema renina angiotensina. 
 
CONCLUSÕES 
A alta prevalência de anormalidades no metabolismo da glicose em 
mulheres hipertensas justifica a necessidade do diagnóstico adequado destas 
alterações. A glicemia de jejum isolada não identifica uma importante parcela da 
população hipertensa com diabetes e tolerância diminuída à glicose. Portanto, as 
mulheres hipertensas com obesidade abdominal e glicemia de jejum entre 90 e 100 
mg/dL devem ser submetidas ao teste oral de tolerância à glicose.  
No que concerne ao tratamento das pacientes com este padrão de 
distribuição de gordura, devemos priorizar a escolha de anti-hipertensivos com 
efeitos metabólicos mais favoráveis. Quando houver a necessidade da utilização de 
diuréticos tiazídicos, devemos ter o cuidado de utilizar as menores doses possíveis, 
na tentativa de evitar a depleção de potássio e prevenir as alterações da homeostase 
da glicose.      
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